1,3-Dimethyl-4,5,6,7-tetrahydroindole | 106345-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,3-Dimethyl-4,5,6,7-tetrahydroindole
• CAS: 106345-23-7
• 化学式: C₁₀H₁₅N
• 分子量: 149.236
• InChiKey: KYCRZORCTYZIIS-UHFFFAOYSA-N

物化性质

• 熔点：
  33-34 °C
• 沸点：
  249.2±9.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  2,4-二甲基-1-氧杂-4-氮杂螺[4.5]癸烷 、 sodium methylate 生成 1,3-Dimethyl-4,5,6,7-tetrahydroindole
  参考文献：
  名称：

  KUXAREV, B. F.;STANKEVICH, V. K.;KUXAREVA, V. A., XIMIYA GETEROTSIKL. SOED., 1986, N 4, 533-535

  摘要：

  DOI：

文献信息

• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Raghavan Subharekha

  公开号：US20130072492A1

  公开（公告）日：2013-03-21

  A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

  公式（I）的化合物，或其药学上可接受的盐，能够调节人体生产环磷鸟苷酸单磷酸酯（“cGMP”）的能力，并且通常适用于治疗和预防与cGMP平衡紊乱有关的疾病。此发明还涉及制备公式I的化合物或其药学上可接受的盐的过程，用于治疗和预防上述疾病以及为此目的制备药物的过程，以及包含公式（I）的化合物或其药学上可接受的盐的药物制剂。
• Oxazolidines. 1. Basic catalytic disproportionation of cyclohexanospiro-2-oxazolidines: Synthesis of N-substituted 4,5,6,7-tetrahydroindoles
  作者：B. F. Kukharev、V. K. Stankevich、V. A. Kukhareva

  DOI：10.1007/bf00542786

  日期：1986.4
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20170312292A1

  公开（公告）日：2017-11-02

  The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
• US9365574B2
  申请人：——

  公开号：US9365574B2

  公开（公告）日：2016-06-14
• KUXAREV, B. F.;STANKEVICH, V. K.;KUXAREVA, V. A., XIMIYA GETEROTSIKL. SOED., 1986, N 4, 533-535
  作者：KUXAREV, B. F.、STANKEVICH, V. K.、KUXAREVA, V. A.

  DOI：——

  日期：——